◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Bafna Pharmaceuticals Limited (BAFNAPH) Financial History

Name: Bafna Pharmaceuticals Limited (BAFNAPH) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Bafna Pharmaceuticals Limited (BAFNAPH) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Chennai, India with about 339 employees. Its market capitalization is roughly ₹8 billion. In the fiscal year ended 2026-03-31, BAFNAPH reported ₹1.5B in revenue and ₹111M in net income.

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company offers its products in various dosage forms, including tablets, capsules, and solid orals.

Interactive charts & full statements →

BAFNAPH Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹1.5B	₹1.5B	₹1.5B	₹1.2B	—
Gross Profit	₹481M	₹428M	₹456M	₹388M	—
Operating Income (EBIT)	₹106M	₹70M	₹74M	₹121M	—
Net Income	₹111M	₹42M	₹74M	₹113M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BAFNAPH Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Total Revenue	₹266M	₹422M	₹383M	₹355M	₹346M	—	—
Gross Profit	₹91M	₹125M	₹110M	₹124M	₹122M	—	—
Operating Income (EBIT)	(₹9M)	₹19M	₹15M	₹28M	₹37M	—	—
Net Income	₹1M	₹28M	₹18M	₹31M	₹34M	—	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BAFNAPH Free Cash Flow History

BAFNAPH Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹1.8B	₹1.5B	₹1.5B	₹1.3B	—
Total Liabilities	₹794M	₹683M	₹668M	₹561M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BAFNAPH viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

SGRL · Shree Ganesh Remedies Limited — ₹9 billion
2005 · SSY Group Limited — HK$8 billion
WANBURY · Wanbury Limited — ₹8 billion
APTX · Apotex Health Corp. — C$8 billion
AMANTA · Amanta Healthcare Limited — ₹7 billion
ZIMLAB · ZIM Laboratories Limited — ₹7 billion
VALIANTLAB · Valiant Laboratories Limited — ₹7 billion
KILITCH · Kilitch Drugs (India) Limited — ₹7 billion

← BAFN All “B” companies BAFS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.